Disproportionality analysis of adverse event signals associated with seven Alzheimer's drugs: insights from the FAERS database. (PubMed, Front Pharmacol) - Oct 10, 2026 - "To compare adverse event reporting patterns for seven Alzheimer's disease (AD) drugs (aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, and memantine) using the FDA Adverse Event Reporting System (FAERS), and to explore potential reporting signals. Distinct reporting profiles were observed across drugs, and several potential ADE signals, including potential unlabeled reporting signals, were identified. These findings may support pharmacovigilance surveillance and hypothesis generation, but should be interpreted as reporting associations rather than evidence of causality."
Adverse events • Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders
|
|
Kai Liu; Lingti Kong; Xiaohu Yang
|